Wells Fargo analyst Stephen Baxter upgraded Pennant Group (PNTG) to Overweight from Equal Weight with a price target of $31, up from $29. The firm sees upside in the stock even with conservative home health reimbursement rate assumptions. Materially improved reimbursement rates provide a a “nearly free” call option at current valuation levels, the analyst tells investors in a research note. Wells says the worse than expected proposed rule for 2026 home health rates has been an overhang on Pennant shares.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PNTG: